Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients
This marks the first IND clearance for initiation of Radspherin® clinical trials in the USOncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2b study for Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer. “We are excited to announce the IND clearance for Radspherin® for colorectal cancer patients following the promising indications of safety